Cargando…
Novel combination therapies for BRAF-mutant melanoma
Autor principal: | McArthur, Grant A |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4315240/ http://dx.doi.org/10.1186/1479-5876-13-S1-K6 |
Ejemplares similares
-
The immune-related role of BRAF in melanoma
por: Tomei, Sara, et al.
Publicado: (2015) -
Grp94-specific monoclonal antibody to counteract BRAF inhibitor resistance in BRAF(V600E) melanoma
por: Sabbatino, F, et al.
Publicado: (2015) -
MEK + CDK4 a regimen for non-BRAF V6000 melanoma
por: Sosman, Jeff
Publicado: (2015) -
Combining targeted and immunotherapy: BRAF inhibitor dabrafenib (D) ± the MEK inhibitor trametinib (T) in combination with ipilimumab (Ipi) for V600E/K mutation-positive unresectable or metastatic melanoma (MM)
por: Puzanov, Igor
Publicado: (2015) -
ErbB3 plays a key role in the early phase of establishment of resistance to BRAF and/or MEK inhibitors
por: Fattore, Luigi, et al.
Publicado: (2015)